GW Pharmaceuticals Fails Mid-Stage Study

UK-based GW Pharmaceuticals (GWPH) announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint. The Phase 2a  study evaluated the efficacy and safety of GWP42006, which features cannabidivarin (CBDV) as the primary cannabinoid molecule. The drug was meant as an add-on treatment for adults with inadequately controlled focal seizures.  Focal seizures are partial seizures that happen when this neural disturbance remains in a limited area of the brain.

The study was conducted primarily in Eastern Europe. The top-line results in both the drug and the placebo showed a drop of approximately 40% in the number of seizures experienced. This was a much higher response from the placebo than had been expected.

GW Pharmaceutical said in a statement that the drug was generally well tolerated. Still, the company stated, “More patients in the active group (73 percent) experienced treatment-emergent adverse events compared to the placebo group (48 percent). A majority of the GWP42006 patients experienced adverse events of mild or moderate severity.

The compound has shown anti-epileptic properties across a range of in vitro and in vivo models of epilepsy. GW Pharmaceuticals said it would continue to look for other opportunities for the compound.

Autism Disorders

In parallel with this study,  GWP42006 was also being evaluated in both general and syndromic pre-clinical models of Autism Spectrum Disorder (ASD)  yielding promising signals on cognitive and social endpoints as well as repetitive behavior.  The company said in  a statement that it would “continue to advance various clinical initiatives within the field of ASD, including a physician-led expanded access IND in 10 patients with autism as well as both open-label and Phase 2 placebo-controlled trials in Rett syndrome, a condition for which GWP42006 has received Orphan Drug Designation from the FDA.” Open-label data from the expanded access IND are expected later in 2018.

“Whilst the results of this adult focal seizure study for GWP42006 are disappointing, we remain committed to advancing this pipeline compound to address unmet needs in the field of autism spectrum disorders, in which a promising body of pre-clinical data has already been generated, as well as continuing to explore the product’s potential within the field of epilepsy,” said Justin Gover, GW’s Chief Executive Officer.

Gover said that Epidiolex remained the top priority for the year. The stock fell almost 6% in after-hours trading to approximately $124.


Debra Borchardt

Debra Borchardt is the Co-Founder, and Executive Editor of GMR. She has covered the cannabis industry for several years at Forbes, Seeking Alpha and TheStreet. Prior to becoming a financial journalist, Debra was a Vice President at Bear Stearns where she held a Series 7 and Registered Investment Advisor license. Debra has a Master's degree in Business Journalism from New York University.

Leave a Reply

Your email address will not be published. Required fields are marked *

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.

 Sign up

About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


Recent Tweets

Back to Top

Get the latest cannabis news delivered right to your inbox

The Morning Rise

Unpack the industry with the daily cannabis newsletter for business leaders.